Hyaluronic-acid-modified lipid-polymer hybrid nanoparticles as an efficient ocular delivery platform for moxifloxacin hydrochloride

Dexmedetomidine and levobupivacaine co-loaded, transcriptional transactivator peptide modified nanostructured lipid carriers or lipid–polymer hybrid nanoparticles, which performed better for local anesthetic therapy?

“…NLCs are reported to have the abilities of biocompatibility, modified release kinetics which are suitable for topical drug delivery (Chen et al, 2012). LPNs are argued to have controlled release capability, high biocompatibility, and favorable pharmacokinetic profile, while may have an influence on the drug transdermal permeation (Zhang et al, 2015;Liu et al, 2018). Drug transdermal permeation included two processes: release from adhesive layer and skin percutaneous permeation (Wang et al, 2019).…”

Advances and limitations of drug delivery systems formulated as eye drops

“…J o u r n a l P r e -p r o o f More recently, HA has also been combined with lipidic NPs to deliver moxifloxacin [115], tacrolimus [116] and doxorubicin [117]. Due to the ability of HA to target CD44 receptor on the corneal epithelial cells, these studies demonstrated an increase of drug bioavailability without significant toxicity.…”

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

“…The HA hydrogel was viscous enough to be injected and was intended to be used as resorbable punctal plugs for the treatment of dry eye disease or as a drug delivery vehicle. Liu et al designed core-shell lipid-polymer hybrid NPs: moxifloxacin hydrochloride-loaded CS NPs, surrounded by a phospholipid layer, bearing HA residues for a more efficient targeting ( Figure 12) [155]. CS NPs were prepared by ionic gelation with TPP, and the lipidic bilayer was set by hydrating a dried lipid film by a NP suspension.…”